ISSN: 1308-5727 | E-ISSN: 1308-5735
Volume : 14 Issue : 3 Year : 2022
Forms

Abstracting & Indexing
Turkish Society for Pediatric Endocrinology and Diabetes
Left Ventricular Hypertrophy in Patients with X-Linked Hypophosphataemia [J Clin Res Pediatr Endocrinol]
J Clin Res Pediatr Endocrinol. 2022; 14(3): 344-349 | DOI: 10.4274/jcrpe.galenos.2021.2020.0287

Left Ventricular Hypertrophy in Patients with X-Linked Hypophosphataemia

Ana Castellano-Martinez1, Silvia Acuñas-soto1, Virginia Roldan-cano1, Moises Rodriguez-Gonzalez2
1Puerta del Mar University Hospital, Department of Pediatric Nephrology, Cadiz, Spain
2Puerta del Mar University Hospital, Department of Pediatric Cardiology, Cadiz, Spain

X-linked hypophosphatemia (XLH) is a rare genetic disorder with X-linked dominant inheritance. Mutations in the PHEX gene increase fibroblast growth factor 23 (FGF23) concentrations, causing loss of phosphorus at the proximal tubule. Most pediatric patients debut in the first two years with short stature and bowed legs. Conventional treatment consists of oral supplements with phosphorus and calcitriol. Since 2018, burosumab has been approved as a novel therapeutic option for XLH, with promising results. The purpose of this study was to share our experience with two cases of XLH treated with burosumab. These patients presented with a broad phenotypical differences. One had the most severe radiological phenotype and developed left ventricular hypertrophy (LVH) and left ventricular dysfunction with preserved ejection fraction. Treatment with burosumab was well-tolerated and was followed by radiological stability and a striking improvement in both blood biochemistry and quality of life. The LVH was stable and left ventricular function normalized in the patient with cardiac involvement. In recent years many studies have been carried out to explain the role of FGF23 in cardiovascular damage, but the exact pathophysiological mechanisms are as yet unclear. The most intensively studied populations are patients with XLH or chronic kidney disease, as both are associated with high levels of FGF23. To date, cardiovascular involvement in XLH has been described in patients treated with conventional treatment, so it would be of interest to investigate if early use of burosumab at the time of diagnosis of XLH would prevent the occurrence of cardiovascular manifestations.

Keywords: X-linked hypophosphataemia, FGF23, arterial hypertension, cardiovascular risk, left ventricular hypertrophy, burosumab

Ana Castellano-Martinez, Silvia Acuñas-soto, Virginia Roldan-cano, Moises Rodriguez-Gonzalez. Left Ventricular Hypertrophy in Patients with X-Linked Hypophosphataemia. J Clin Res Pediatr Endocrinol. 2022; 14(3): 344-349

Corresponding Author: Ana Castellano-Martinez, Spain
Manuscript Language: English
LookUs & Online Makale